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More than 115 years ago, it was demonstrated by Von Mering and Minkowski that pancreatec-
tomy produced diabetes mellitus in dogs (I). Nearly four decades passed before attempts were 
made to restore glucose homeostasis by pancreas transplantation with surgical vascular anasto-
moses, but only for physiologic experiments (2,3). An additional three decades went by before 
preclinical studies for the potential purpose of ameliorating diabetes were undertaken in the late 
1950s by Brooks and Gifford (4) and DeJode and Howard (5). After surgical technical problems 
were worked out in the canine model (summarized in Ref. 6), the first attempt to treat human dia-
betes mellitus with pancreas transplantation was carried out on December 17, 1966, by William 
Kelly and Richard Lillehei (7) at the University of Minnesota. The patient died after two months. 
The same Minneapolis team recorded the first success on June 3, 1969 (8). "Success" during this 
pioneer period came to be defined as patient and functional graft survival for at least one year. 
Thus, the pancreas became the fourth kind of organ allograft to be successfully trans-
planted over a lO-year period (1959-1969) in which the feasibility of kidney (9,10), liver (11), 
and heart (12) already had been demonstrated (Table 1) (8-13). It was a stunning "proof of prin-
ciple" development that was at first considered not credible by knowledgeable authorities who 
had viewed such efforts with distain. Hopes for organ transplantation had been based pre-
viously on experiments in neonatal mice (14) and in irradiated adult mice (15) in which it 
was shown that the development of donor-specific tolerance was associated with the donor leu-
kocyte chimerism produced by splenic or bone marrow cell infusion. In an extrapolation of the 
mouse findings, the production of donor leukocyte chimerism by bone marrow infusion prior to 
or at the time of organ transplantation was expected to play an essential role in achieving organ 
engraftment. However, efforts to apply this strategy in animals were uniformly unsuccessful, in 
part because a good histocompatibility match was a prerequisite for avoidance of graft versus 
host disease. When discovery of the human leukocyte antigens made tissue matching feasible, 
human bone marrow transplantation was finally accomplished, but this was not until 1968 (13). 
In the meanwhile, two unexplained qualities of the alloimmune response had made it 
feasible to forge ahead precociously with organ transplantation under drug immunosuppres-
sion (16). The first observation was that kidney allograft rejection that developed under 
azathioprine was regularly reversible by adding large doses of prednisone. The second finding 
was that organ allografts under the nonspecific immunosuppression of azathioprine and pre-
dnisone appeared to self-induce variable donor-specific tolerance. Tolerance was inferred from 
the rapidly declining need for immunosuppression after rejection reversal. However, because 
of the ostensible absence of donor leukocyte chimerism in these recipients, organ engraftment, 
including that of the pancreas, was attributed to different mechanisms than those of bone mar-
row cell engraftment. This chimerism-exclusionary dogma was not challenged until low-level 
(micro-) chimerism was discovered in 1992 in the blood and tissues of long-surviving organ 
recipients (17,18). Then it was obvious that alloengraftment was a form of partial tolerance 
that resulted from" ... responses of co-existing donor and recipient cells, each to the other, 
causing reciprocal clonal exhaustion, followed by peripheral clonal deletion" (Fig. 1) (17,18). 
Successfully treated organ recipients and bone marrow recipients were mirror image versions 
of leukocyte chimerism, differing in the proportion of donor and recipient leukocytes (Fig. 2). 
THE DOMINANT ROLE OF DRUG IMMUNOSUPPRESSION 
Without the foregoing insight into the chimerism-dependent mechanisms of organ 
engraftment, further progress hinged almost exclusively on the development of stronger 
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Table 1 First Successful Transplantation of Human Allografts (Survival 2': 1 Year) 
Organ City (Re!.) Dale Physician/surgeon 
Kidney Boston (9,10) 1/24/59 MerrilllMurray 
Liver Denver (11) 7/23/67 StarzllGroth 
Heart Cape Town (12) 1/2/68 Barnard 
Bone marrow Minneapolis (13) 8/24/68 Gatti/Good 
Pancreas' Minneapolis (8) 6/3169 LilieheilKelly 
aKiclney and pancreas allografts in uremic patient. 
immunosuppression. The combined use of azathioprine and prednisone had been a critical 
step in the clinical development of kidney and other kinds of organ transplantation. But 
because allografts were being lost to acute rejections that could not be reversed, a worldwide 
policy drift occurred in which large doses of prednisone were administered from the time of 
operation, rather than in response to rejection. The addition in 1966 of a short course of post-
transplant antilymphocyte globulin (ALG) to azathioprine and prednisone (the "triple drug 
cocktail") substantially reduced steroid needs (19,20) and was used for the first successful non-
renal organ transplantations (8,11,12). Nevertheless, the heavy mortality, and particularly the 
devastating morbidity caused by long-term prednisone dependence, made organ transplan-
tation (even of kidneys) as much a disease as a treatment in the view of critics. Widespread 
transplantation of the nonrenal organs (including the pancreas) was forestalled until the 
advent of cyclosporine (21,22) and tacrolimus (23). 
As the more potent drugs became available, they were simply folded into the modified 
formula of heavy prophylactic immunosuppression that had been inherited from the 1960s and 
1970s. Used in this way, the multiple drug cocktails fueled the golden age of transplantation of 
the 1980s and early 1990s. The dose ceilings of the individual primary and secondary drugs 
were imposed by drug toxicity, while the dose floors were revealed by breakthrough rejection. 
For example, the upper limit of azathioprine dosage [or comparably used substitutes such as 
cyclosphosphamide (24) or mycophenolate mofetil (MMF) (25)] was dictated by myelotoxicity 
that could be monitored conveniently by serial white blood counts. The more complex limiting 
side effects of the ca1cineurin inhibitors (cyclosporine and tacrolimus) are shown in Table 2. Of 
specific interest in the context of pancreas transplantation, both cyclosporine and tacrolimus 
are diabetogenic, in addition to their nephrotoxicity and neurotoxicity (26). The other T-cell 
directed agent, sirolimus, has its own distinctive panoply of dose-limiting side effects (27). 
By using these agents in different combinations, it was possible with the various drug 
cocktails to reduce acute rejection to almost a non-problem during the last two decades. 
The unresolved issues now became the drug-specific side effects, chronic rejection, and the 
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Figure 1 Contemporaneous host versus graft (HVG) (upright curves) and graft versus host (GVH) (inverted curves) 
responses after organ transplantation. If some degree of reciprocal clonal exhaustion is not induced and maintained 
(usually requiring protective immune suppression), one cell population will destroy the other. In contrast to the usually 
dominant HVG reaction of organ transplantation (shown here), the GVH reaction usually is dominant in the cytoablated 
bone marrow recipient. Therapeutic failure with either type of transplantation implies the inability to control one, the 
other, or both of the responses. 
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Figure 2 Two-way paradigm in which transplantation is seen as a bidirectional and mutually canceling immune reaction 
that is predominantly host versus graft with whole organ grafts (lem and predominantly graft versus host with bone 
marrow grafts (right). 
risks of long-term immunodepression. The list of complications from protracted immunode-
pression per se was a long one, which could be divided into two broad categories: 
susceptibility to infections and the development of de novo malignancies. 
PANCREAS TRANSPLANT PROCEDURES VS. IMMUNOSUPPRESSION ERA 
Neither the development nor the merits of the different pancreas transplant operations could 
be discussed intelligently without parallel consideration of the immunosuppression that was 
available at the time these procedures were introduced. The point can be most easily made by 
perusing the 1988 textbook, Pancreatic Transplantation, prepared by Carl G. Groth (Huddinge 
Hospital, Huddinge, Sweden) (28) after it was apparent that cyclosporine had upgraded the 
prospects for a range of organ transplant procedures. In addition to the contributions by 
the Stockholm team members, Groth's book contains chapters from the seminal Minneapolis 
pancreas program and from programs in Cambridge (England), Iowa City, Lyon, Munich, and 
Pittsburgh. Because it provides a snapshot of pancreas transplantation in transition, the book 
is a historical treasure. In its pages, opinions about surgical technique, pancreas procurement 
and preservation, and other issues were discussed (circa 1987) by team leaders who continued 
to influence pancreas transplantation for the next dozen years and beyond. 
Azathioprine Era 
The first attempts at clinical pancreas transplantation were plagued by inadequate control of 
rejection despite the administration of frequently myelotoxic doses of azathioprine, large 
Table 2 Nonimmunologic Profile of Calcineurin Inhibitors (Four + Worst): All Dose 
Related 
Tacrolimus Cyclosporine 
Nephrotoxicity ++a ++ 
Neurotoxicity + + 
Diabetogenicity + + 
Growth effects 
Hirsutism 0 +++ 
Gingival hyperplasia 0 ++ 
Facial brutalization 0 + 
Hepatotropic effects ++++ +++ 
Gynecomastia 0 + 
Other metabolic effects 
Cholesterol increase 0 ++ 
Uric acid increase +? ++ 
'Less hypertension. 
Source: From Ref. 26. 
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amounts of prednisone, and "induction" ALG. In addition to being diabetogenic, steroids 
were inimical to wound healing. The technical aspects of the pancreas transplant procedures 
developed during this period reflected efforts to work around these inadequacies of immuno-
suppression. In their first human operation at the University of Minnesota (7) on December 17, 
1966, Kelly and Lillehei transplanted the head and tail of a cadaveric pancreas to the left iliac 
fossa of a uremic recipient after removing the graft duodenum and ligating the pancreatic 
duct. A kidney from the same donor was placed in the right iliac fossa. The recipient 
immediately became insulin independent, but died at two months from a combination of 
rejection and sepsis. 
By 1973, Lillehei and associates had implanted 13 more whole human pancreas grafts, 10 
in combination with cadaver kidneys from the same donor and the final three alone (8,29). 
In cases 2 to 6 pancreatic secretions of the allograft were exteriorized (cutaneous graft duode-
nostomy), while in cases 7 to 13 the exocrine drainage was directed via the graft duodenum 
into the host jejunum, using a Roux-en Y technique (8). In patient 14, a patch of graft 
duodenum containing the ampulla of Vater was anastomosed to recipient bowel. The only recipi-
ent (the sixth) in this pioneer series of 14 cases to achieve long-lasting insulin independence 
beginning on the day of operation (June 3, 1969) died shortly after reaching the one-year mile-
stone with a functioning pancreas after losing the kidney graft and returning to dialysis. The 
13 other pancreas graft losses resulted from technical complications including vascular throm-
bosis, death with a functioning graft, and, most commonly, lethal complications associated with 
exocrine pancreatic drainage. Similar discouraging results with pancreas transplantation during 
the early 1970s in Sao Paulo (Brazil), Chicago (lllinois), Irvine (California), Zurich (Switzerland), 
and in mostly unreported cases elsewhere caused abandonment of whole organ pancreas 
transplantation for more than a decade. 
The grim early experience continued to influence surgical policies worldwide until the 
end of the 20th century. With the premise that the Achilles heel of the operation was the need 
for exocrine drainage, new strategies emerged to avoid entry into the host bowel, to eliminate 
the graft duodenum from the graft or to prevent or reduce the volume of the graft 
exocrine secretions. In 1973, Gliedman et al. (30) reported excision of the graft duodenum 
and the adjacent pancreatic head with transplantation of the rest of the pancreas; the segmen-
tal pancreatic duct was anastomosed to the recipient ureter. When two of these recipients lived 
insulin free for two and four years (31), momentum shifted for the next dozen years to the 
essentially exclusive use of distal pancreas grafts. Rather than exocrine diversion into the uri-
nary tract or bowel, however, most surgeons either drained exocrine secretions from the 
pancreatic segment into the free peritoneal cavity or blocked the segmental duct by ligation (29) 
or by injection of a polymer (32). Only Groth and Tyden in Stockholm systematically resisted 
the trend by anastomosing the duct (or the draining segmental surface) to the bowel (33). 
Cyclosporine Era 
With better control of rejection and less steroid dependence made possible by cyclosporine, 
there was a resurgence of interest in pancreas transplantation as well as modifications of 
the surgical operation. Use of segmental cadaveric allografts continued until well into the 
1980s, and remains an option today when live pancreas donors are used. In early 1982, we 
re-examined the reasons for abandonment of whole pancreas transplantation, and undertook 
reassessment of the procedure in dogs (34). Our conclusion was that the most logical operation 
of whole organ transplantation described by Lillehei and Kelly had been discontinued in 
favor of the inferior option of segmental pancreas transplantation. Consequently, a limited 
clinical trial of whole organ pancreas transplantation was begun in Pittsburgh in March 
1983 (35). In a crucial modification of the original Lillehei procedure, we developed a tech-
nique for draining the allograft exocrine secretions into the host jejunum through a "bubble" 
of graft duodenum into which the ampulla of Vater emptied. The duodenal bubble was 
anastomosed to the side of the host jejunum (Fig. 3) (35,36). 
Although the number of cases was small, the influence of the trial was amplified by the 
presence in Pittsburgh at the time of fellows or visitors who had come to observe the burgeon-
ing liver transplant program and who also saw how easy and successful was the whole organ 
pancreas transplantation. One such fellow (1981-1983), Dr. Munci Kalayoglu, subsequently 
joined a team at the University of Wisconsin headed by Dr. Hans Sollinger, which had 
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Figure 3 Use of donor "duodenal bubble" for exo-
crine pancreatic drainage introduced in Pittsburgh in 
1983. 
previously compiled a series of segmental transplantations with exocrine drainage into the 
bladder. After Kalayoglu's arrival in Madison, Sollinger and Kalayoglu changed from segmen-
tal to whole organ transplantation. Similarly, Dr. Robert Corry of the University of Iowa was 
persuaded during a sabbatical leave in Pittsburgh in late 1983 and early 1984 to adopt the 
whole pancreas transplantation procedure (37). 
At their home institutions, Corry and Sollinger initially drained the graft duodenal bub-
ble into the host jejunum. However, both teams soon advocated anastomosis of the bubble to 
the anterolateral wall of the host bladder (Fig. 4) (38,39). Bladder drainage was adopted soon 
thereafter for most cases at the University of Minnesota (39). With the enthusiastic endorse-
ment from these three centers [reflected in separate chapters in Groth's book (40-42») the 
bladder drainage technique was widely accepted. Serial measurement of urine amylase con-
centration became a means of immune surveillance, i.e., a drop in urine amylase signaled 
rejection. Complications from the bladder drainage were initially viewed as acceptable. 
However, digestion of the urethra by activated pancreatic enzymes, less serious but common 
examples of cystitis, uncorrectable metabolic acidosis caused by the continuous loss of 
bicarbonate, and a myriad of other problems necessitating conversion to enteric drainage 
began to diminish enthusiasm for bladder drainage by the mid 1990s. By this time, Corry 
(now at the University of Pittsburgh) had switched back to enteric drainage via the duodenal 
bubble. After the advent of tacrolimus, this became the reconstruction of choice at almost all 
centers (43-45). 
Tacrolimus Era 
Despite Corry's enthusiastic advocacy of tacrolimus, the drug was not widely used for pan-
creas transplantation until the mid 1990s because of its dose-related diabetogenicity. This view 
changed dramatically when a multicenter collection of cases demonstrated the ability of the 
new drug to rescue most of the treatment failures that were occurring under cyclosporine-
based immunosuppression (46). Moreover, the superior control of rejection with minimal 
dependence on prednisone using tacrolimus-based immunosuppression from the outset has 
further eroded the arguments for exocrine diversion to the bladder. It also became possible 
with the simplified tacrolimus-based regimens to eliminate the perioperative induction 
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Figure 4 Drainage of pancreas exocrine secretions into the recipient bladder. This was the most commonly used 
procedure from 1985 until the mid or late 1990s. 
therapy with ALG that had become a standard component of cyclosporine-based immuno-
suppression during the mid 1980s. Since 1995, general agreement about the superiority of 
tacrolimus-based immunosuppression was finally reached (33,43-45,47-49). 
A New Era? 
The long-term efficacy of pancreas transplantation is not yet clear. Only 16 recipients in the 
world are known to have functioning pancreas allografts that were transplanted before 1986 
and none who were treated before 1981 (50). With the improvements that occurred since the 
1980s, there have been many reports indicating that the survival of diabetic kidney trans-
plant recipients is improved by cotransplantation of a pancreas (43-49). However, there 
has been at least one United Network for Organ Sharing-based analysis suggesting that 
the risk of death from staged kidney-pancreas transplantation has been greater, even in 
recent times, than in kidney-alone recipients who had been listed for a pancreas but failed 
to get one (51) (see also counter-arguments in Chapter 1). Apart from pancreas graft-related 
complications or functional failures, late recipient deaths have continued from cardiac, infec-
tious, and peripheral vascular disease, and from de novo malignancies. Many, if not most, of 
these late complications can be traced to, or are aggravated by, the need for chronic 
imm unos u ppression. 
The ideal solution would be to make organ recipients more tolerant and thereby less 
immunosuppression-dependent. This objective became realistic with the elucidation of the 
donor leukocyte chimerism-associated mechanisms of acqUired tolerance (17,18) and 
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Figure 5 Mechanisms of immunosuppression_ (Left): Conversion of rejection (thick dashed arrow) to an immune 
response that can be exhausted and deleted by combination of pretreatment and minimalistic posttransplant 
immunosuppression. Eoigh~: If the clonal response is eliminated by excessive posttransplant immunosuppression, 
exhaustion-deletion shown on the left is precluded, and subsequent graft survival is permanently dependent on 
immunosuppression. Abbreviations: GVH, graft versus host; HVG, host versus graft; Tx, transplantation. 
the recognition that organ engraftment is a form of partial tolerance (52,53). With this insight, it 
was obvious that the seminal mechanism of alloengraftment and acquired tolerance (i.e., clo-
nal exhaustion-deletion) can be subverted by the "conventional" use of heavy prophylactic 
immunosuppression (Fig. 5, right) (53). In 2001, it was proposed that this undesired conse-
quence could be prevented by observance of two therapeutic principles: recipient pretreatment 
and the use of minimal posttransplant immunosuppression (Fig. 5, left) (53). 
Between July and December 2001, the late Robb Corry carried out a pilot trial based on 
these principles in 10 recipients of simultaneous pancreas and kidney allografts and four 
recipients of pancreas transplants alone. All of the donors were human leukocyte antigen-
mismatched, heart-beating cadavers with the same ABO types as the recipients. The patients 
were infused prior to organ revascularization with approximately 5 mg/kg rabbit antithymo-
cyte globulin (Thymoglobulin lt) and were coinfused with 1-2g methylprednisolone to 
prevent cytokine reactions (54). On the first postoperative day, twice-daily tacrolimus 
monotherapy was begun with a target 12-hour trough level of 10 ng/ mL. After four to six 
months, patients who had been on stable tacrolimus monotherapy for at least two months 
had extension of the interval of tacrolimus doses ("spaced weaning") to once a day, every 
other day, or longer if this was compatible with stable graft function (Fig. 6). 
A short-term follow-up of the patients was reported in 2003 (54). The results at three 
years and the current results are summarized in Table 3 for each case. Eleven (78%) of the 
14 recipients remained insulin free for three years, but in two of these patients, hyperglycemia 
recurred after 36 months. Thus, nine (64.2%) still are insulin free after 43 to 49 months. Eight of 
the nine insulin-free patients are on treatment with a Single drug and four are on spaced doses 
of tacrolimus (Figs. 6 and 7). Importantly, seven of the 10 patients who also received kidneys 
had life-supporting renal function at three years with serum creatinine concentrations <::;2 mg/ 
dL in six. After Corry was killed in a motor vehicular accident in February 2002, the trial was 
placed on hold. 
By the time of his death, Corry was aware that the management principles under evalu-
ation were sound and required only fine-tuning. First, the initial step of weaning to every 
other day would have to be taken more cautiously. Second, weaning of monotherapy to inter-
vals greater than every other day should be delayed until at least one year unless evidence of 
drug-specific side effects (e.g., nephrotoxicity, neurotoxicity, or diabetogenicity) called for ear-
lier action. In 2003, the policy of tolerogenic immunosuppression was reinstituted with these 
foregOing modifications. In addition, lymphoid depletion was done with the broadly reacting 
antilymphoid monoclonal antibody, alemtuzumab (Campath@) rather than with Thymoglobu-
lin. The superior early results with this management are described in Chapter 1. The chapter, 
along with the rest of this book, has been dedicated to Corry's memory. A Robb Corry 
Professorship has been established at the University of Pittsburgh, the inaugural occupant 
of which is Ron Shapiro. 
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Figure 6 The course of a simultaneous 
pancreas-kidney recipient pretreated with 
antithymocyte globulin. The dose frequency 
of daily monotherapy was reduced to every 
other day at four months and to three times 
a week at eight months after transplant (top 
panel). Creatinine, lipase, glucose, and C· 
peptide (middle panels), have been stable 
throughout. This patient did not receive 
any steroids or other additional treatment 
and was biopsied five times with no evidence 
of damaging acute rejection. 
35 Table 3 Tolerogenic Immunosuppression for Pancreas Recipients (Corry, 2001): Results at Three Years 
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Monolherapy Creatinine Fasting glucose 
Number TX (dose frequency) (mg/dl) (mg/dl) 
Simultaneous pancreas-kidney 
1 7/01 Daily 2.0 80-90 
2 8/01 Daily 1.3 80-100 
3 8/01 Once/wk 1.0 70-80' 
4 9/01 Failed 22 rna Failed 5 rno 
5 9/01 Daily 4 90-100 
6 10/01 Failed 22 mo 90-140b 
7 11/01 Thrice/wk 1.0 80-100 
8 11/01 Daily 1.7 80-110 
9 12/01 Failed 13 rno Failed 7 rna 
10 12/01 Thrice/wk 1.3 80-90 
Pancreas alone 
1 7/01 Thrice/wk 1.7c 70-100 
2 9/01 Daily multidrug 1.2c 90-140b 
3 10/01 1.0c Failed 5 mo 
4 12/01 Daily 1.6c 70-90 
Monotherapy: all tacrolimus except Case 1 (rapamycin). 
-, Not applicable because of graft loss(s) and drug discontinuance. 
'After three years, the patient developed disseminated metastases from breast cancer, and died insulin-free at 43 months. 
"Became insulin-dependent after three years. 
CNative kidney. 
Note: Pancreas grafts functioning at three years: 11/14 (78.5%). currently 9/14 (64%); kidney grafts functioning at three years and 
now: 7/10 (70%). 
Abbreviation: TX, transplantation. 
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Figure 7 The course of the first pancreas 
recipient pretreated with antithymocyte 
globulin. The dose frequency for this pan~ 
creas-alone recipient was reduced quickly 
after six months reaching a minimum of 
one dose per week at one year. A bioche-
mically indicated, pathology-confirmed 
rejection at 23 months was reversed with 
steroids, a dose of alemtuzumab (lower 
panel), and the temporary resumption of 
daily tacrolimus that suosequently was 
re-weaned to three times a week. The 
benefit of recluced exposure to tacrolimus 
is apparent in the creatinine levels depicted 
in the second panel; i.e., the patient's kid-
ney functioned better with less treatment 
and worse with more treatment. Other than 
during the rejection episode, graft function, 
as reflected in the lipase, glucose, and c~ 
peptide levels, has been stable throughout. 
Later patients (Fig. 6) were weaned less 
aggressively. 
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